Christos Fountzilas, MD
Roswell Park Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Christos Fountzilas, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 13:29 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT04511039 · Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal CancerRoswell Park Cancer Institute · recruiting · Advanced Malignant Solid Neoplasm, Clinical Stage III Gastroesophageal Junction Adenocarcinoma, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma · principal investigator
- Ph2NCT04119830 · Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal CancerRoswell Park Cancer Institute · withdrawn · Metastatic Colorectal Adenocarcinoma, Microsatellite Stable, Mismatch Repair Proficient · principal investigator
- Ph2NCT04109924 · TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO StudyRoswell Park Cancer Institute · completed · Advanced Colorectal Carcinoma, Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 13:29 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Novel synthetic lethality strategy for TP53 mutant colorectal cancerR37CA282430 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Christos Fountzilas · fiscal years 2023 to 2026Named on NCT04511039
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in colorectal cancer.